Clinical Trials Browser

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Depression

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Disease Progression

Breast Neoplasms

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms, Recurrence

Breast Neoplasms, Triple Negative Breast Neoplasms

Brain Neoplasms, Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Clinical Trials

CONFIRM

TAILORx

VERITAC-2

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

TB06

MNEMOSYNE

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

HER2CLIMB-05

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

OPERA-02

NoLEEta

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

OPERA-01

MK-2870-010

VITACAL

Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment

KEYNOTE-B49

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

INAVO123

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

DB-06

NATALEE

DEBRA

OFSET

HEAL-ABC

ReDiscover-2

Adjuvant WIDER

FourLight-3

MECCA

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

CAPIcorn

CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

POWER II

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

EPIK-B5

OlympiA

A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction

OlympiAD

DISCORDANT

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

POLARIS

DESTINY-B12

OLIGAMI

A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer